Atea Pharmaceuticals, Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

Having ended work with its polymerase inhibitor bemnifosbuvir in treating COVID-19 infections, Atea Pharmaceuticals is returning to its original focus on hepatitis C and reported Phase II data for a c

It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l

Having jumped in front of the UK's Redx Pharma Plc to snap up Jounce Therapeutics, Inc. , Concerta Biosciences is looking to bag another embattled biotech, making a bid for the US antiviral speci